Ana Bocanegra - Concepedia

Author

Ana Bocanegra

Also Known As

A Bocanegra, A. Bocanegra, A.I. Bocanegra, A.I. Bocanegra Gondan, Alberto Velasco, Ana Bocanegra, Ana I. Bocanegra, Ana Isabel Bocanegra, Ana Isabel Bocanegra Gondan

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Navarrabiomed Navarre Institute of Health Research Complejo Hospitalario de Navarra Universidad de Navarra Universidad Publica de Navarra

About

Ana Bocanegra is an author at Navarrabiomed specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	341
2	Engineering	2	2	155
3	Biomedical Engineering	2	2	155
4	Health Sciences	1	1	16
5	Biomolecular Engineering	1	1	55

Ana Bocanegra

Publications

814

Citations

H-Index

Page 1

	Year	Citations
Functional systemic <scp>CD</scp> 4 immunity is required for clinical responses to <scp>PD</scp> ‐L1/ <scp>PD</scp> ‐1 blockade therapy Miren Zuazo, Hugo Arasanz, G. Fernández-Hinojal, EMBO Molecular Medicine	2019	211
Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles Ana Bocanegra, Ane Ruiz‐de‐Angulo, Aintzane Zabaleta, Biomaterials NanoparticlesNanomedicineTumor ImmunologyMagnetic NanoparticlesEngineering	2018	100
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer Ana Bocanegra, G. Fernández-Hinojal, Miren Zuazo-Ibarra, International Journal of Molecular Sciences Tumor ImmunologyCancer ImmunosurveillancePd-l1 ExpressionMedicineImmunology	2019	73
Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics Hugo Arasanz, Miren Zuazo, Ana Bocanegra, Cancers	2020	65
Triple-Labeling of Polymer-Coated Quantum Dots and Adsorbed Proteins for Tracing their Fate in Cell Cultures Carolina Carrillo‐Carrión, Ana Bocanegra, Blanca Arnáiz, ACS Nano NanoparticlesEngineeringColloidal NanocrystalsAdsorbed ProteinsBiomedical Engineering	2019	55
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy Marta Redondo-Muñoz, Francisco Javier Rodríguez‐Baena, Paula Aldaz, Nature Metabolism	2023	44
Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer Hugo Arasanz, Ana Bocanegra, Idoia Morilla, Cancers Cancer ImmunosurveillanceBaseline LdnsMedicineMalignant Blood DisorderImmunology	2022	35
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy Miren Zuazo, Hugo Arasanz, M.J. García Granda, Annals of Oncology Clinical ImmunologyCancer ImmunosurveillanceAutoimmune DiseaseClinical ResponsesImmunology	2019	33
Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy Miren Zuazo, Hugo Arasanz, Ana Bocanegra, EMBO Molecular Medicine	2020	30
The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in Melanoma Irene Otero, Iker Feliu, Alberto Maillo, Journal of Investigative Dermatology	2022	27

Page 1